Chen J, Hua Q, Wang H, et al. - Researchers here indirectly compared the effectiveness as well as toxicity of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) in the treatment of advanced pancreatic cancer (PC), by conducting this network meta-analysis. They identified eligible retrospective studies on treatments associated with modified FOLFIRINOX and GEM-NAB up to 4 April 2020. They analyzed 22 studies. According to current evidence, similar survival and toxicity were found between modified FOLFIRINOX and GEM-NAB. Consideration should be given to many factors in the formulation of optimal treatment, and this study could offer some guidance to treatment choice in the first-line setting for advanced PC.